Loading...

EXAS

Exact Sciences Corporation · NASDAQ

Performance

-5.98%

1W

-21.25%

1M

-29.81%

3M

-34.89%

6M

-43.04%

YTD

-53.74%

1Y

Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Investment Analysis Report: EXAS

Overview

In this investment analysis report, we will delve into the financial statements of Exact Sciences Corporation (EXAS) to evaluate its investment potential. We will analyze the Balance Sheets, Income Statements, and Cashflow Statements to gain insights into the company's financial health, growth prospects,...

See more ...

Technical Analysis of EXAS 2024-05-31

Overview:

In analyzing the technical indicators for EXAS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potential inv...

See more ...

Recent News & Updates